2022
Modeling the cost‐effectiveness and impact on fatal overdose and initiation of buprenorphine–naloxone treatment at syringe service programs
Adams JW, Savinkina A, Fox A, Behrends CN, Madushani RWMA, Wang J, Chatterjee A, Walley AY, Barocas JA, Linas BP. Modeling the cost‐effectiveness and impact on fatal overdose and initiation of buprenorphine–naloxone treatment at syringe service programs. Addiction 2022, 117: 2635-2648. PMID: 35315148, PMCID: PMC9951221, DOI: 10.1111/add.15883.Peer-Reviewed Original ResearchConceptsSyringe services programFatal opioid overdosesBuprenorphine-naloxone treatmentOpioid use disorderTreatment initiationBuprenorphine treatmentOpioid overdosesFatal overdosesSSP clientsActive opioid useCommunity treatment providersObservational cohort studyNational surveillance dataCost-effectiveness analysisCohort studyIntervention scenariosOpioid useBuprenorphine programOUD treatmentStatus quo scenarioClinical trialsFatal overdoseMore QALYsUse disordersTreatment engagement
2021
Projected Long-Term Impact of the Coronavirus Disease 2019 (COVID-19) Pandemic on Hepatitis C Outcomes in the United States: A Modeling Study
Barocas JA, Savinkina A, Lodi S, Epstein RL, Bouton TC, Sperring H, Hsu HE, Jacobson KR, Schechter-Perkins EM, Linas BP, White LF. Projected Long-Term Impact of the Coronavirus Disease 2019 (COVID-19) Pandemic on Hepatitis C Outcomes in the United States: A Modeling Study. Clinical Infectious Diseases 2021, 75: e1112-e1119. PMID: 34499124, PMCID: PMC8522427, DOI: 10.1093/cid/ciab779.Peer-Reviewed Original ResearchConceptsLiver-related deathPre-pandemic levelsHepatitis C outcomesCoronavirus disease 2019 (COVID-19) pandemicCOVID-19-related disruptionsPre-pandemic ratesDisease 2019 pandemicHCV careHCV outcomesVirologic responseHCV epidemicTreatment initiationPandemic-related disruptionsCare disruptionsC outcomesAdditional casesCare servicesCare deliveryCirrhosisHCVHealthcare deliveryCOVID-19COVID-19 pandemicAggressive effortsOutcomes